| scholarly article | Q13442814 |
| review article | Q7318358 |
| P50 | author | Alexander Karaulov | Q4214390 |
| Musa Khaitov | Q30345117 | ||
| Yury Zhernov | Q91298392 | ||
| Julia Eckl-Dorna | Q74807378 | ||
| P2093 | author name string | Rudolf Valenta | |
| Birgit Linhart | |||
| Sergio Villazala-Merino | |||
| Verena Niederberger-Leppin | |||
| P2860 | cites work | Immunological mechanisms of allergen-specific immunotherapy | Q28265326 |
| Flexible IgE epitope containing domains of Phl p 5 cause high allergenic activity | Q30402299 | ||
| Amb a 1-immunostimulatory oligodeoxynucleotide conjugate immunotherapy decreases the nasal inflammatory response | Q75436624 | ||
| Evolution of IgM, IgE and IgG(1-4 )antibody responses in early childhood monitored with recombinant allergen components: implications for class switch mechanisms | Q77596622 | ||
| Induction of antibody responses to new B cell epitopes indicates vaccination character of allergen immunotherapy | Q77924919 | ||
| Blocking antibodies induced by specific allergy vaccination prevent the activation of CD4+ T cells by inhibiting serum-IgE-facilitated allergen presentation | Q78145327 | ||
| Detection and characterization of plasma cells in peripheral blood: correlation of IgE+ plasma cell frequency with IgE serum titre | Q78576565 | ||
| Immunotherapy with a ragweed-toll-like receptor 9 agonist vaccine for allergic rhinitis | Q79189373 | ||
| Combination treatment with omalizumab and rush immunotherapy for ragweed-induced allergic rhinitis: Inhibition of IgE-facilitated allergen binding | Q80614064 | ||
| Functional rather than immunoreactive levels of IgG4 correlate closely with clinical response to grass pollen immunotherapy | Q82473859 | ||
| Decreases in human dendritic cell-dependent T(H)2-like responses after acute in vivo IgE neutralization | Q82786335 | ||
| Sublingual grass pollen immunotherapy is associated with increases in sublingual Foxp3-expressing cells and elevated allergen-specific immunoglobulin G4, immunoglobulin A and serum inhibitory activity for immunoglobulin E-facilitated allergen bindin | Q83034447 | ||
| SQ-standardized sublingual grass immunotherapy: confirmation of disease modification 2 years after 3 years of treatment in a randomized trial | Q83346456 | ||
| Nasal application of rBet v 1 or non-IgE-reactive T-cell epitope-containing rBet v 1 fragments has different effects on systemic allergen-specific antibody responses | Q84624034 | ||
| Basophil expression of diamine oxidase: a novel biomarker of allergen immunotherapy response | Q86131523 | ||
| Birch pollen immunotherapy results in long-term loss of Bet v 1-specific TH2 responses, transient TR1 activation, and synthesis of IgE-blocking antibodies | Q87394685 | ||
| Immunological comparison of allergen immunotherapy tablet treatment and subcutaneous immunotherapy against grass allergy | Q87684784 | ||
| Effect of omalizumab treatment on peripheral eosinophil and T-lymphocyte function in patients with allergic asthma. | Q52932526 | ||
| Treatment of allergic asthma with monoclonal anti-IgE antibody. rhuMAb-E25 Study Group. | Q53535114 | ||
| Role of IgG4 in IgE-mediated allergic responses. | Q53740730 | ||
| Molecular Aspects of Allergens and Allergy. | Q53825271 | ||
| Omalizumab's Impact on Total and Allergen-Specific IgE Levels: A Polyclonal Story. | Q54153454 | ||
| Physicochemical properties of reaginic antibody. V. Correlation of reaginic activity wth gamma-E-globulin antibody. | Q54456350 | ||
| Anti-Inflammatory Activity of Human IgG4 Antibodies by Dynamic Fab Arm Exchange | Q55178105 | ||
| Treating cat allergy with monoclonal IgG antibodies that bind allergen and prevent IgE engagement. | Q55277398 | ||
| Allergen-specific nasal IgG antibodies induced by vaccination with genetically modified allergens are associated with reduced nasal allergen sensitivity | Q57267001 | ||
| Structure of a patient-derived antibody in complex with allergen reveals simultaneous conventional and superantigen-like recognition | Q58700268 | ||
| Long-term tolerance after allergen immunotherapy is accompanied by selective persistence of blocking antibodies | Q60312277 | ||
| Transfer of Symptomatic Peanut Allergy to the Recipient of a Combined Liver-And-Kidney Transplant | Q60609080 | ||
| Serologic aspects of IgG4 antibodies. II. IgG4 antibodies form small, nonprecipitating immune complexes due to functional monovalency | Q61601629 | ||
| Skin test evaluation of a novel peptide carrier-based vaccine, BM32, in grass pollen-allergic patients. | Q64910571 | ||
| The metabolism of IgE. Studies in normal individuals and in a patient with IgE myeloma | Q67835847 | ||
| Allergen presentation by epidermal Langerhans' cells from patients with atopic dermatitis is mediated by IgE | Q68496650 | ||
| Diagnosis of allergy by an in-vitro test for allergen antibodies | Q70079015 | ||
| Serum-IgE-facilitated allergen presentation in atopic disease | Q70649043 | ||
| Human IgG monoclonal antibodies that modulate the binding of specific IgE to birch pollen Bet v 1 | Q71384793 | ||
| Effect of immunotherapy on immunoglobulin E and immunoglobulin G antibodies to ragweed antigens: a six-year prospective study | Q71620176 | ||
| The high affinity IgE receptor (Fc epsilon RI) mediates IgE-dependent allergen presentation | Q72260696 | ||
| Immunologic characterization of monoclonal antibodies that modulate human IgE binding to the major birch pollen allergen Bet v 1 | Q73128460 | ||
| Bip 1, a monoclonal antibody with specificity for the major birch pollen allergen Bet v 1, modulates IgE binding to the allergen | Q73295718 | ||
| The effect of an anti-IgE monoclonal antibody on the early- and late-phase responses to allergen inhalation in asthmatic subjects | Q73442941 | ||
| In vitro IgE inhibition in B cells by anti-CD23 monoclonal antibodies is functionally dependent on the immunoglobulin Fc domain | Q73469868 | ||
| Nasal provocation with allergen induces a secondary serum IgE antibody response | Q73807369 | ||
| Antigens drive memory IgE responses in human allergy via the nasal mucosa. | Q51978305 | ||
| Dimerization of the major birch pollen allergen Bet v 1 is important for its in vivo IgE-cross-linking potential in mice. | Q51987397 | ||
| Genetic restriction of antigen-presentation dictates allergic sensitization and disease in humanized mice. | Q52313895 | ||
| Quantitative IgE- and IgG-subclass responses during and after long-term ragweed immunotherapy | Q52421818 | ||
| Time course of serum inhibitory activity for facilitated allergen-IgE binding during bee venom immunotherapy in children. | Q52697877 | ||
| Role of mast cells in allergic and non-allergic immune responses: comparison of human and murine data | Q31096289 | ||
| Persistence of IgE-associated allergy and allergen-specific IgE despite CD4+ T cell loss in AIDS. | Q33711875 | ||
| IgG antibodies produced during subcutaneous allergen immunotherapy mediate inhibition of basophil activation via a mechanism involving both FcgammaRIIA and FcgammaRIIB. | Q33770788 | ||
| Effects of omalizumab on basophil and mast cell responses using an intranasal cat allergen challenge | Q33774675 | ||
| Long-term clinical efficacy of grass-pollen immunotherapy | Q33870492 | ||
| Anti-IgE (omalizumab) inhibits late-phase reactions and inflammatory cells after repeat skin allergen challenge | Q33990027 | ||
| Local IgE production | Q34078267 | ||
| Facilitated antigen presentation and its inhibition by blocking IgG antibodies depends on IgE repertoire complexity. | Q34168771 | ||
| IgG4 production is confined to human IL-10-producing regulatory B cells that suppress antigen-specific immune responses | Q34330562 | ||
| Costimulation blockade inhibits allergic sensitization but does not affect established allergy in a murine model of grass pollen allergy | Q34361871 | ||
| Down-regulation of Fc(epsilon)RI expression on human basophils during in vivo treatment of atopic patients with anti-IgE antibody. | Q34414866 | ||
| IgE antibody measurements in ragweed hay fever. Relationship to clinical severity and the results of immunotherapy | Q34499562 | ||
| Different modes of IgE binding to CD23 revealed with major birch allergen, Bet v 1-specific monoclonal IgE. | Q34508199 | ||
| Effects of nasal corticosteroids on boosts of systemic allergen-specific IgE production induced by nasal allergen exposure | Q35113146 | ||
| The high molecular weight glutenin subunit Bx7 allergen from wheat contains repetitive IgE epitopes. | Q35190821 | ||
| IgA and IgG anti-ragweed antibodies in nasal secretions. Quantitative measurements of antibodies and correlation with inhibition of histamine release | Q35200077 | ||
| Renaissance of the blocking antibody concept in type I allergy | Q35557996 | ||
| Development and characterization of a recombinant, hypoallergenic, peptide-based vaccine for grass pollen allergy. | Q35566610 | ||
| Immunotherapy of allergic disease | Q35671703 | ||
| The IgE-facilitated allergen binding (FAB) assay: validation of a novel flow-cytometric based method for the detection of inhibitory antibody responses | Q35915934 | ||
| On the prediction of the human response: a recycled mechanistic pharmacokinetic/pharmacodynamic approach. | Q36055566 | ||
| Genetics of allergy and allergic sensitization: common variants, rare mutations | Q36176674 | ||
| SEROLOGICAL EVIDENCE OF IMMUNITY WITH COEXISTING SENSITIZATION IN A TYPE OF HUMAN ALLERGY (HAY FEVER). | Q36256769 | ||
| Effect of grass pollen immunotherapy on clinical and local immune response to nasal allergen challenge | Q36784749 | ||
| Structural basis of omalizumab therapy and omalizumab-mediated IgE exchange. | Q36919753 | ||
| Fifty years later: Emerging functions of IgE antibodies in host defense, immune regulation, and allergic diseases | Q36983081 | ||
| IgE responses to exogenous and endogenous allergens in atopic dermatitis patients under long-term systemic cyclosporine A treatment | Q37106475 | ||
| Mechanisms, safety and efficacy of a B cell epitope-based vaccine for immunotherapy of grass pollen allergy | Q37309704 | ||
| Vaccination with genetically engineered allergens prevents progression of allergic disease. | Q37569798 | ||
| A B Cell Epitope Peptide Derived from the Major Grass Pollen Allergen Phl p 1 Boosts Allergen-Specific Secondary Antibody Responses without Allergen-Specific T Cell Help | Q37625474 | ||
| An assay that may predict the development of IgG enhancing allergen-specific IgE binding during birch immunotherapy | Q37660273 | ||
| CD23 surface density on B cells is associated with IgE levels and determines IgE-facilitated allergen uptake, as well as activation of allergen-specific T cells. | Q37660379 | ||
| Critical and direct involvement of the CD23 stalk region in IgE binding. | Q37660384 | ||
| The who, where, and when of IgE in allergic airway disease. | Q37968359 | ||
| What is the source of serum allergen-specific IgE? | Q38098954 | ||
| Effect of 2 Years of Treatment With Sublingual Grass Pollen Immunotherapy on Nasal Response to Allergen Challenge at 3 Years Among Patients With Moderate to Severe Seasonal Allergic Rhinitis: The GRASS Randomized Clinical Trial | Q38380837 | ||
| News in Cellular Allergology: A Review of the Human Mast Cell and Basophil Granulocyte Literature from January 2013 to May 2015. | Q38741162 | ||
| Biomarkers for monitoring clinical efficacy of allergen immunotherapy for allergic rhinoconjunctivitis and allergic asthma: an EAACI Position Paper. | Q39115606 | ||
| Maximal rise in IgE antibody following ragweed pollination season | Q39312524 | ||
| Mechanisms of immune regulation in allergic diseases: the role of regulatory T and B cells. | Q39402881 | ||
| Inhibition of CD23-dependent facilitated allergen binding to B cells following vaccination with genetically modified hypoallergenic Bet v 1 molecules | Q39684020 | ||
| Evolution of the IgE and IgG repertoire to a comprehensive array of allergen molecules in the first decade of life. | Q40089613 | ||
| Anti-CD23 monoclonal antibody, lumiliximab, inhibited allergen-induced responses in antigen-presenting cells and T cells from atopic subjects | Q40364862 | ||
| IgE‐mediated antigen presentation | Q40483815 | ||
| Persistent IgE synthesis in the nasal mucosa of hay fever patients | Q40591918 | ||
| Effects of immunotherapy on the early, late, and rechallenge nasal reaction to provocation with allergen: changes in inflammatory mediators and cells | Q40749921 | ||
| Local production of IgG, IgA and IgE antibodies in grass pollen hay fever | Q40868372 | ||
| The IgG subclasses of antibodies to grass pollen allergens produced in hay fever patients during hyposensitization | Q40890377 | ||
| Antigen focusing by specific monomeric immunoglobulin E bound to CD23 on Epstein-Barr virus-transformed B cells | Q41555930 | ||
| IgE-dependent antigen focusing by human B lymphocytes is mediated by the low-affinity receptor for IgE. | Q41729246 | ||
| Microarrayed dog, cat, and horse allergens show weak correlation between allergen-specific IgE and IgG responses | Q42388102 | ||
| Immunotherapy decreases antigen-induced eosinophil cell migration into the nasal cavity | Q43561164 | ||
| Omalizumab, anti-IgE recombinant humanized monoclonal antibody, for the treatment of severe allergic asthma | Q43701894 | ||
| Relationship between facilitated allergen presentation and the presence of allergen-specific IgE in serum of atopic patients | Q44216307 | ||
| Total and allergen-specific IgE in relation to allergic response pattern following bone marrow transplantation. | Q44252385 | ||
| Immunological and clinical changes in allergic asthmatics following treatment with omalizumab | Q44448943 | ||
| Studies on the mechanisms of hypersensitivity phenomena. XVI. In vitro assays of reaginic activity in human sera: effect of therapeutic immunization on seasonal titer changes | Q44488613 | ||
| Allergen-specific immunotherapy with a monophosphoryl lipid A-adjuvanted vaccine: reduced seasonally boosted immunoglobulin E production and inhibition of basophil histamine release by therapy-induced blocking antibodies. | Q44574133 | ||
| Subclass typing of IgG antibodies formed by grass pollen-allergic patients during immunotherapy | Q44601767 | ||
| Histamine release from peripheral blood leukocytes with purified bee venom allergens: effect of hyperimmune beekeeper plasma | Q44901293 | ||
| Effects of treatment with anti-immunoglobulin E antibody omalizumab on airway inflammation in allergic asthma | Q44917836 | ||
| Synchronous Immune Alterations Mirror Clinical Response During Allergen Immunotherapy. | Q45072722 | ||
| A quantitative in vitro study of the chromatographic distribution and immunoglobulin characteristics of human blocking antibody. | Q45144519 | ||
| Omalizumab attenuates airway inflammation and interleukin-5 production by mononuclear cells in patients with severe allergic asthma | Q45385408 | ||
| Development of an in vitro system for the study of allergens and allergen-specific immunoglobulin E and immunoglobulin G: Fcepsilon receptor I supercross-linking is a possible new mechanism of immunoglobulin G-dependent enhancement of type I allergi | Q46559696 | ||
| A double-blind placebo-controlled birch allergy vaccination study II: correlation between inhibition of IgE binding, histamine release and facilitated allergen presentation | Q46569103 | ||
| Grass pollen immunotherapy: IL-10 induction and suppression of late responses precedes IgG4 inhibitory antibody activity | Q46675736 | ||
| Mechanisms of allergen immunotherapy for inhaled allergens and predictive biomarkers | Q47314389 | ||
| IgE-expressing memory B cells and plasmablasts are increased in blood of children with asthma, food allergy and atopic dermatitis. | Q47644093 | ||
| Safety and efficacy of immunotherapy with the recombinant B-cell epitope-based grass pollen vaccine BM32. | Q47649812 | ||
| Applications and mechanisms of immunotherapy in allergic rhinitis and asthma | Q47653403 | ||
| Molecular characterization of human IgG monoclonal antibodies specific for the major birch pollen allergen Bet v 1. Anti-allergen IgG can enhance the anaphylactic reaction. | Q47895314 | ||
| A double-blind, placebo-controlled birch allergy vaccination study: inhibition of CD23-mediated serum-immunoglobulin E-facilitated allergen presentation | Q47988492 | ||
| Grass pollen immunotherapy induces mucosal and peripheral IL-10 responses and blocking IgG activity. | Q48016882 | ||
| Intranasal administration of allergen increases specific IgE whereas intranasal omalizumab does not increase serum IgE levels-A pilot study. | Q48104072 | ||
| Immunological differences between insect venom-allergic patients with and without immunotherapy and asymptomatically sensitized subjects. | Q48243376 | ||
| A randomized, double-blind, placebo-controlled, dose-finding trial with Lolium perenne peptide immunotherapy. | Q48278642 | ||
| Lolium perenne peptides for treatment of grass pollen allergy: A randomized, double-blind, placebo-controlled clinical trial | Q49054245 | ||
| IgE+ B cells are scarce, but allergen-specific B cells with a memory phenotype circulate in patients with allergic rhinitis. | Q50760318 | ||
| Human IgE(+) B cells are derived from T cell-dependent and T cell-independent pathways. | Q50848337 | ||
| Cell-free detection of allergen-IgE cross-linking with immobilized phase CD23: inhibition by blocking antibody responses after immunotherapy. | Q50857544 | ||
| The majority of allergen-specific IgE in the blood of allergic patients does not originate from blood-derived B cells or plasma cells. | Q50941015 | ||
| Inhibition of allergen-IgE binding to B cells by IgG antibodies after grass pollen immunotherapy. | Q51644402 | ||
| Grass pollen immunotherapy for hayfever is associated with increases in local nasal but not peripheral Th1:Th2 cytokine ratios. | Q51727137 | ||
| P275 | copyright license | Creative Commons Attribution 4.0 International | Q20007257 |
| P407 | language of work or name | English | Q1860 |
| P921 | main subject | immunity | Q182581 |
| globulins | Q321710 | ||
| blood proteins | Q425056 | ||
| Allergen-specific immunotherapy | Q57111909 | ||
| P304 | page(s) | 3131 | |
| P577 | publication date | 2018-01-01 | |
| 2019-01-17 | |||
| P1433 | published in | Frontiers in Immunology | Q27723748 |
| P1476 | title | Allergen-Specific Antibodies Regulate Secondary Allergen-Specific Immune Responses | |
| P478 | volume | 9 |
| Q90423881 | Mechanisms of allergen-specific immunotherapy for allergic rhinitis and food allergies |
| Q98177685 | Preventive Allergen-Specific Vaccination Against Allergy: Mission Possible? |
| Q90219041 | Relationship between serum inhibitory activity for IgE and efficacy of Artemisia pollen subcutaneous immunotherapy for allergic rhinitis: a preliminary self-controlled study |
| Q100945957 | Towards middle-up analysis of polyclonal antibodies: subclass-specific N-glycosylation profiling of murine immunoglobulin G (IgG) by means of HPLC-MS |
| Q92988172 | Tracing IgE-Producing Cells in Allergic Patients |
Search more.